Andrew Jay Bierman, FNP-C

Andrew Bierman practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Andrew Bierman's NPI, 1306408505, was assigned on July 8, 2019. Andrew Bierman holds California license 95011909.

Andrew Bierman's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Andrew Bierman's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians. Dmand AI also links Andrew Bierman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Andrew Bierman practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Andrew Bierman's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Andrew Bierman is licensed in California.

CMS data shows 97 Medicare services from Andrew Bierman across 2 procedure codes in 2024, for 84 Medicare patients. Medicare paid $6,643 for them. Every service was in an office.

CMS counts 84 Medicare patients who saw Andrew Bierman in 2024. The largest group is under 65, with 35 patients. 68% of them have high cholesterol, and 50% have arthritis. 36% are also on Medicaid. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Andrew Bierman's median patient age at 49, with 74% women.

In 2024, Andrew Bierman wrote 1,072 Medicare Part D claims for 245 patients. 77% of them were for generic drugs. CMS names the drug for 760 of them, across 24 drugs with 11 or more claims each, at $1,007,868 in total drug cost.

Andrew Bierman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Andrew Bierman as offering telehealth.

CMS Open Payments shows 41 general payments to Andrew Bierman from 9 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 69% of the total. Genentech, Inc. paid the most, $4,378.